Canada is set to emerge as a key contender in the global race to produce generic versions of Ozempic, the popular diabetes medication, as manufacturers prepare for accelerated approvals and exciting new market opportunities on the horizon
Eli Lilly’s recent launch of its weight-loss drug in India is set to transform the competitive landscape of the burgeoning market. With obesity rates rising, rivals are now poised to accelerate their efforts to capture a share of this lucrative opportunity.